Grace Therapeutics reports FY2025 net loss of $9.6M; NDA for GTx-104 on track for June 2025 submission

Grace Therapeutics, Inc.

Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.
R&D expenses rose to $9.5M (FY2024: $4.7M) due to the STRIVE-ON Phase 3 trial; cash at $22.1M.
NDA for GTx-104 for aSAH expected to be submitted to FDA by end of June 2025 following positive Type C meeting.
Secured $15M upfront private placement (led by Nantahala Capital, ADAR1 Partners) with potential $15M from warrants.
STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.